Hemolytic Uremic Syndrome (HUS) Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
Condition: Atypical Hemolytic Uremic Syndrome Intervention: Drug: Cemdisiran Sponsor: Alnylam Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2017 Category: Research Source Type: clinical trials
